{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/diabetes-type-2/","result":{"data":{"firstChapter":{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field e0a1254e-c647-4bb8-b659-1978af02f1c9 --><h1>Summary: Diabetes - type 2</h1><!-- end field e0a1254e-c647-4bb8-b659-1978af02f1c9 -->","htmlStringContent":"<!-- begin item 3f1ed932-3379-45d7-b1b6-8d7064c09d89 --><!-- begin field 3b3136b8-09d7-41a3-be87-3d12a13c00fe --><ul><li>Type 2 diabetes mellitus is a metabolic disorder in which persistent hyperglycaemia (HbA1c more than 48 mmol/mol [6.5%] or random plasma glucose more than 11.1 mmol/L) is caused by a combination of deficient insulin secretion and resistance to the action of insulin.<br><ul><li>Risk factors include obesity and inactivity; diet; family history of type 2 diabetes; Asian, African, and Afro-Caribbean ethnicity; drug treatments such as long-term corticosteroids; and history of gestational diabetes.</li><li>Diabetes is one of the most common chronic diseases in the UK and can occur in all age groups. Its prevalence is increasing, including in children.</li></ul></li><li>Possible complications include:<ul><li>Macrovascular — cardiovascular disease (CVD) including ischaemic heart disease, stroke disease, and peripheral arterial disease.</li><li>Microvascular — diabetic kidney disease, retinopathy, peripheral and autonomic neuropathy.</li><li>Foot problems — including foot ulcer, deformity, infection, and Charcot arthropathy.</li><li>Metabolic — dyslipidaemia, potentially life-threatening hyperglycaemic emergencies (diabetic ketoacidosis and hyperosmolar hyperglycaemic state).</li><li>Psychosocial impact — including anxiety, depression, eating disorders, behavioural and emotional problems.</li><li>Reduced life expectancy.</li></ul></li><li>Suspect a diagnosis of type 2 diabetes if there is:<ul><li>Persistent hyperglycaemia.</li><li>Possible clinical features, such as polydipsia, polyuria, weight loss, tiredness; enuresis, behavioural changes, and impaired growth (in children); signs of acanthosis nigricans (suggesting insulin resistance).</li></ul></li><li>Management of a person with type 2 diabetes should include:<ul><li>Ensuring they have an individualized care plan, taking into account their age, preferences, co-morbidities, and risks and benefits of treatment.</li><li>Offering adults referral to a structured group education programme, and ensuring children are referred to a multidisciplinary diabetes team for confirmation of the diagnosis and ongoing management.</li><li>Advising on sources of information and support.</li><li>Advising on always wearing or carrying some form of diabetes identification.</li><li>Advising on lifestyle measures, such as diet, exercise and physical activity, weight loss, smoking, alcohol, and drug misuse.</li><li>Advising on how to manage intercurrent illness and 'sick-day rules'.</li><li>Assessing for associated psychosocial problems and offering support.</li><li>Advising on sexual health, contraception, and pre-pregnancy counselling, if appropriate.</li><li>Offering immunization against influenza and pneumococcal infection, if indicated.</li><li>Advising on the importance of regular HbA1c monitoring, antidiabetic drug treatment (if appropriate), and individualized treatment targets, to reduce the risk of long-term complications.</li><li>Advising against routine self-monitoring of blood glucose levels.</li><li>Advising on the importance of regular screening for complications, how to reduce risk, and offering management as appropriate.</li><li>Ensuring young people are supported in the transition from paediatric to adult services.</li></ul></li></ul><!-- end field 3b3136b8-09d7-41a3-be87-3d12a13c00fe --><!-- end item 3f1ed932-3379-45d7-b1b6-8d7064c09d89 -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","aliases":["Type 2 diabetes"],"chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","slug":"management","fullItemName":"Management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","aliases":["Type 2 diabetes"],"topicSummary":"Diabetes mellitus is a group of metabolic disorders characterized by persistent hyperglycaemia (HbA1c more than 48 mmol/mol [6.5%]","lastRevised":"Last revised in January 2021","nextPlannedReviewBy":"2026-01-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2026-01","nextPlannedReviewByDisplay":"January 2026","specialities":[{"id":"fe645ae3-9536-5dfb-8c84-285b62195550","name":"Cardiovascular","slug":"cardiovascular"},{"id":"aa304738-44fc-5b1d-af3b-42cce5d27663","name":"Endocrine and metabolic","slug":"endocrine-metabolic"},{"id":"485bdd1b-4437-5374-838e-f1f1db61a424","name":"Eyes","slug":"eyes"},{"id":"f72b3ad6-0501-5364-8469-e48bd9b988b9","name":"Kidney disease and urology","slug":"kidney-disease-urology"},{"id":"2454765b-1b2d-53fc-b288-17b66486f41a","name":"Preventative medicine","slug":"preventative-medicine"}],"chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","slug":"management","fullItemName":"Management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57"}},"staticQueryHashes":["3666801979"]}